In GOLD-RCC, patients received sorafenib third-line after disease progression on or within 6 months of the most recent of two prior therapies including one VEGF inhibitor and one mammalian target of rapamycin (mTOR) inhibitor [77,82,83]. Here, MTOR is linked to renal cell carcinoma.